You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775

Article metrics

Article menu

Download PDFPDF

Endometrial cancer
2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to October 2024

AbstractFullPdf
Oct 20224808
Nov 202277018
Dec 2022108028
Jan 2023133013
Feb 202372012
Mar 202398025
Apr 202310008
May 2023139011
Jun 20234405
Jul 202373011
Aug 202394012
Sep 20237806
Oct 202391012
Nov 202385011
Dec 202381013
Jan 20244207
Feb 202479016
Mar 202474013
Apr 202476012
May 20247505
Jun 20246409
Jul 20244408
Aug 20243205
Sep 20243604
Oct 20241400
Total18570272